{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:22:40Z","timestamp":1769556160088,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"AstraZeneca USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13048-016-0227-x","type":"journal-article","created":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T08:00:15Z","timestamp":1458633615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer \u2013 an observational cohort study"],"prefix":"10.1186","volume":"9","author":[{"given":"Sudhir K.","family":"Unni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa B.","family":"Schauerhamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi","family":"Deka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy E.","family":"Tyczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ancilla W.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana I.","family":"Brixner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Stenehjem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,22]]},"reference":[{"key":"227_CR1","unstructured":"Cancer of the Ovary - SEER Stat Fact Sheets [Internet]. SEER. [cited 2015 May 14]. Available from: http:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html"},{"key":"227_CR2","first-page":"1","volume-title":"Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer v3.2014","author":"NCCN","year":"2012","unstructured":"NCCN. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer v3.2014. 2012. p. 1\u201377."},{"issue":"29","key":"227_CR3","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699\u2013707.","journal-title":"J Clin Oncol"},{"issue":"9375","key":"227_CR4","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MKB Parmar","year":"2003","unstructured":"Parmar MKB, Ledermann JA, Colombo N, Bois du A, Delaloye J-F, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099\u2013106.","journal-title":"Lancet"},{"issue":"3","key":"227_CR5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2012.03.006","volume":"125","author":"RB Dann","year":"2012","unstructured":"Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD, et al. BRCA1\/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2012;125(3):677\u201382.","journal-title":"Gynecol Oncol"},{"issue":"37","key":"227_CR6","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1038\/sj.onc.1206678","volume":"22","author":"SN Powell","year":"2003","unstructured":"Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene. 2003;22(37):5784\u201391.","journal-title":"Oncogene"},{"issue":"2","key":"227_CR7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","volume":"108","author":"AR Venkitaraman","year":"2002","unstructured":"Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171\u201382.","journal-title":"Cell"},{"issue":"11","key":"227_CR8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1349-7006.2004.tb02195.x","volume":"95","author":"K Yoshida","year":"2004","unstructured":"Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95(11):866\u201371.","journal-title":"Cancer Sci"},{"issue":"2","key":"227_CR9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMe0903044","volume":"361","author":"JD Iglehart","year":"2009","unstructured":"Iglehart JD, Silver DP. Synthetic lethality\u2015a New direction in cancer-drug development. N Engl J Med. 2009;361(2):189\u201391.","journal-title":"N Engl J Med"},{"issue":"7","key":"227_CR10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ctrv.2010.03.006","volume":"36","author":"E Amir","year":"2010","unstructured":"Amir E, Seruga B, Serrano R, Ocana A. Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treat Rev. 2010;36(7):557\u201365.","journal-title":"Cancer Treat Rev"},{"issue":"22","key":"227_CR11","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","volume":"28","author":"PAP Konstantinopoulos","year":"2010","unstructured":"Konstantinopoulos PAP, Spentzos DD, Karlan BYB, Taniguchi TT, Fountzilas EE, Francoeur NN, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28(22):3555\u201361.","journal-title":"J Clin Oncol"},{"issue":"12","key":"227_CR12","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","volume":"104","author":"T Pal","year":"2005","unstructured":"Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807\u201316.","journal-title":"Cancer"},{"issue":"3","key":"227_CR13","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","volume":"68","author":"HA Risch","year":"2001","unstructured":"Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68(3):700\u201310.","journal-title":"Am J Hum Genet"},{"key":"227_CR14","first-page":"1","volume-title":"Infrastructure To Monitor Utilization and Outcomes of Gene-Based Applications: An Assessment","author":"F DeStefano","year":"2008","unstructured":"DeStefano F, Whitehead N, Lux LJ, Lohr KN. Infrastructure To Monitor Utilization and Outcomes of Gene-Based Applications: An Assessment. Rockville: Agency for Healthcare Research and Quality; 2008. p. 1\u2013100. Report No.: No. 08- EHC012."},{"issue":"14","key":"227_CR15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","volume":"306","author":"Y Da","year":"2011","unstructured":"Da Y, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306(14):1557\u201365.","journal-title":"JAMA"},{"issue":"2","key":"227_CR16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.molonc.2009.02.001","volume":"3","author":"SJ Ramus","year":"2009","unstructured":"Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 2009;3(2):138\u201350.","journal-title":"Mol Oncol"},{"issue":"15","key":"227_CR17","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1002\/cncr.26655","volume":"118","author":"DM Hyman","year":"2012","unstructured":"Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer. 2012;118(15):3703\u20139. Wiley Subscription Services, Inc., A Wiley Company.","journal-title":"Cancer"},{"issue":"1","key":"227_CR18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","volume":"21","author":"Q Zhong","year":"2014","unstructured":"Zhong Q, Peng H-L, Zhao X, Zhang L, Hwang W-T. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res. 2014;21(1):211\u201320.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-016-0227-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T09:00:48Z","timestamp":1498294848000},"score":1,"resource":{"primary":{"URL":"http:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-016-0227-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,22]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["227"],"URL":"https:\/\/doi.org\/10.1186\/s13048-016-0227-x","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,22]]},"article-number":"18"}}